Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Introduction

  • In recent clinical trials of antiretroviral-naive patients, the proportion of patients achieving undetectable HIV-1 RNA was approximately 90%
  • For some patients there are often important, nonvirologic reasons to modify their antiretroviral regimen, such as drug intolerance or the need to simplify the regimen

With currently available antiretroviral agents, it is possible to design simple and safe virologically suppressive HIV treatment regimens for antiretroviral-naive and most—if not all—antiretroviral-experienced patients. Indeed, in recent clinical trials of antiretroviral-naive patients, the proportion achieving undetectable HIV-1 RNA was approximately 90%. Once the goal of achieving undetectable HIV-1 RNA (eg, < 50 copies/mL) has been accomplished, most patients will likely continue treatment with the same antiretroviral regimen for many years without any need for change. However, for some there are often important, nonvirologic reasons to modify their antiretroviral regimen, such as for drug intolerance or to simplify the regimen.

...

Action required

Keywords: Switch Strategies